A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects with Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Project Details

StatusActive
Effective start/end date5/07/217/07/23

Funding

  • AbbVie Pty Ltd: A$16,510.00
  • AbbVie Pty Ltd: A$46,323.00